NasdaqGS - Nasdaq Real Time Price • USD
Syros Pharmaceuticals, Inc. (SYRS)
As of 11:52 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.87 | -0.91 | -3.69 | -3.34 |
| Low Estimate | -1.2 | -1.21 | -4.77 | -4.94 |
| High Estimate | -0.69 | -0.69 | -2.8 | -1.05 |
| Year Ago EPS | -0.85 | -1.3 | -5.81 | -3.69 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 720k | 720k | 2.8M | 32.08M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 1.8M | 1.8M | 7M | 130.4M |
| Year Ago Sales | 2.95M | -- | 9.94M | 2.8M |
| Sales Growth (year/est) | -75.60% | -- | -71.80% | 1,045.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.09 | -1.13 | -1.14 | -1.14 |
| EPS Actual | -0.85 | -1.3 | -1.43 | -2.18 |
| Difference | 0.24 | -0.17 | -0.29 | -1.04 |
| Surprise % | 22.00% | -15.00% | -25.40% | -91.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.87 | -0.91 | -3.69 | -3.34 |
| 7 Days Ago | -0.87 | -0.91 | -3.69 | -3.34 |
| 30 Days Ago | -0.95 | -1.05 | -4.11 | -3.08 |
| 60 Days Ago | -0.95 | -1.05 | -4.11 | -3.08 |
| 90 Days Ago | -0.95 | -1.05 | -4.11 | -3.08 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SYRS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -2.40% | -- | -- | 0.80% |
| Next Qtr. | 30.00% | -- | -- | 9.60% |
| Current Year | 36.50% | -- | -- | 4.50% |
| Next Year | 9.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Piper Sandler: Overweight to Overweight | 4/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/1/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 10/3/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/11/2023 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 5/11/2023 |
Related Tickers
HOWL Werewolf Therapeutics, Inc.
5.88
+0.17%
BDTX Black Diamond Therapeutics, Inc.
5.30
0.00%
RANI Rani Therapeutics Holdings, Inc.
6.31
+4.26%
AMLX Amylyx Pharmaceuticals, Inc.
1.9750
-0.25%
SVRA Savara Inc.
4.7600
-0.63%
URGN UroGen Pharma Ltd.
13.66
-4.21%
ALXO ALX Oncology Holdings Inc.
15.82
+0.51%
PBYI Puma Biotechnology, Inc.
4.9800
-0.20%
ANAB AnaptysBio, Inc.
19.86
+0.15%
MCRB Seres Therapeutics, Inc.
0.5760
-1.40%